Richard I. Fisher, M.D.
See information for Patients. Viewing information for Researchers.
Current Appointments
- Director, Univ. of Rochester Medical Faculty Group - Department of Office of VP for Health Sciences (URMC)
- Vice President, URMC - Department of Office of VP for Health Sciences (URMC)
- Senior Associate Dean, Clinical Affairs - Department of Dean's Office, SMD (SMD)
- Director - Cancer Center (SMD)
- Samuel E. Durand Chair in Medicine - Department of Medicine (SMD)
- Professor - Department of Medicine (SMD)
| Journal Articles |
|---|
| Showing 274 journal articles currently available. |
| Hilchey, S.P.; Hyrien, O.; Mosmann, T.R.; Livingstone, A.M.; Friedberg, J.W.; Young, F.; Fisher, R.I.; Kelleher Jr., R.J.; Bankert, R.B. and Bernstein, S.H. "Rituximab Immunotherapy Results in the Induction of a Lymphoma Idiotype-Specific T-Cell Response in Patients with Follicular Lymphoma: Support for a "Vaccinal Effect" of Rituximab." Blood (2009). |
| Dasmahapatra, G.; Lembersky, D.; Rahmani, M.; Kramer, L.; Friedberg, J.; Fisher, R.I.; Dent, P., and Grant, S. "Bcl-2 Antagonists Interact Synergistically with Bortezomib in DLBCL Cells in Association with JNK Activation and Induction of ER Stress." Cancer Biology & Therapy 8 (2009): 1-12. |
| Goy, A.; Berstein, S.H.; Kahl, B.S.; Djulbegovic, B.; Robertson, M.J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J.P.; Lonial, S.; Nasta, S.; O'Connor, O.A; Shi, H.; Boral, A.L.; Fisher, R.I. "Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Time-To-Event Analyses of the Multicenter Phase 2 PINNACLE Study." Annals of Oncology 20 (2009): 520-525. |
| Stopeck, A.T.; Unger, J.; Rimsza, L.M.; Bellamy, W.T.; Iannone, M.; Persky, D.O.; LeBlanc, M.; Fisher, R.I. and Miller, T.P. "A Phase II Trial of Single Agent Bevacizumab in Patients with Relapsed, Aggressive Non-Hodgkin Lymphoma; Southwest Oncology Group Study S0108." Leukemia and Lymphoma 50 (2009): 728-735. |
| Friedberg, JW; Kelly, J; Neuberg, D; Peterson, D; Kutok, JL; Salloum, R; Brenn, T; Fisher, DC; Ronan, E; Dalton, V; Rich, L; Marquis, D; Rothberg, P; Liesveld, J; Fisher, RI; Coffman, R; Mosmann, T; Freedman, AS. "Phase II study of a TLR-9 agonist (1018 ISS) with Rituximab in patients with relapsed or refractory follicular lymphoma". Brit J Heme 146 (2009): 282-291. |
| Nguyen, T.K.; Jordan, N.; Friedberg, J.; Fisher, R.I.; Dent, P.; Grant, S. "Inhibition of MEK/ERK 1/2 Sensitizes Lymphoma Cells to Sorafenib-Induced Apoptosis". Leukemia Research (2009). |
| Bernstein, SH; Unger, JM; LeBlanc, M; Friedberg, J; Miller, TP; Fisher, R.I. "The Natural History of Central Nervous System (CNS) Relapse in Patients with Aggressive Non-Hodgkin's Lymphoma: A 20 Year Follow-Up Analysis of Southwest Oncology Group (SWOG) 8516". Journal of Clinical Oncology 27 (2009): 114-119. |
| Friedberg, J.W. and Fisher, R.I. In Cheson, B.D. (Ed). "Diffuse Large B-Cel Lymphoma". Heme/Onc Clinic N. America 22 (2008): 941-952. |
| Mendler, J.H.; Kelly, J.; Voci, S.; Marquis, D.; Rich, L.; Rossi, R.M.; Bernstein, S.H.; Jordan, C.T.; Liesveld, J.; Fisher, R.I.; and Friedberg, J.W. "Bortezomib and Gemcitabine in Relapsed or Refractory Hodgkins Lymphoma." Annals of Oncology 19 (2008): 1759-1764. |
| Swinnen, L.J.; LeBlanc, M.; Grogan, T.M.; Gordon, L.I.; Stiff, P.J.; Miller, A.M.; Kasamon, Y.; Miller, T.P.; and Fisher, R.I. "Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Post-Transplantation Lymphoproliferative Disorder (PTLD)." Transplantation 88 (2008): 215-222. |
| Lenz, G.; Wright, G.W.; Emre, T.; Kohlhammer, H.; Dave, S.S.; Davis, R.E.; Carty, S.; Lam, L.T.; Shaffer, A.L.; Xiao, W.; Powell, J.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H.K.; Gascoyne, R.D.; Connors, J.M.; Campo, E.; Jaffe, E.S.; Delabie, J.; Smeland, E.B.; Rimsza, L.M.; Fisher, R.I.; Weisenburger, D.D.; Chan, W.C. and Staudt, L.M. "Gene Expression Subtypes of Diffuse Large B cell lymphoma Arise by Distinct Genetic Pathways." Proceedings of the National Academy of Science 105 (2008): 20-25. |
| Lenz G; Davis RE; Ngo VN; Lam L; George TC; Wright GW; Dave SS; Zhao H; Xu W; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Chan WC; Staudt LM. "Oncogenic CARD11 mutations in human diffuse large B cell lymphoma." Science (New York, N.Y.). 2008; 319(5870):1676-9. Epub 2008 Mar 06. |
| Lenz G; Wright G; Dave SS; Xiao W; Powell J; Zhao H; Xu W; Tan B; Goldschmidt N; Iqbal J; Vose J; Bast M; Fu K; Weisenburger DD; Greiner TC; Armitage JO; Kyle A; May L; Gascoyne RD; Connors JM; Troen G; Holte H; Kvaloy S; Dierickx D; Verhoef G; Delabie J; Smeland EB; Jares P; Martinez A; Lopez-Guillermo A; Montserrat E; Campo E; Braziel RM; Miller TP; Rimsza LM; Cook JR; Pohlman B; Sweetenham J; Tubbs RR; Fisher RI; Hartmann E; Rosenwald A; Ott G; Muller-Hermelink HK; Wrench D; Lister TA; Jaffe ES; Wilson WH; Chan WC; Staudt LM; . "Stromal gene signatures in large-B-cell lymphomas." The New England journal of medicine. 2008; 359(22):2313-23. |
| Barr, P; Fisher, R.I.; and Friedberg, J. "The Role of Bortezomib in the Treatment of Lymphoma." Cancer Investigation (2007): 1-10. |
| Cheson BD; Pfistner B; Juweid ME; Gascoyne RD; Specht L; Horning SJ; Coiffier B; Fisher RI; Hagenbeek A; Zucca E; Rosen ST; Stroobants S; Lister TA; Hoppe RT; Dreyling M; Tobinai K; Vose JM; Connors JM; Federico M; Diehl V; . "Revised response criteria for malignant lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007; 25(5):579-86. Epub 2007 Jan 22. |
| Lenz G; Nagel I; Siebert R; Roschke AV; Sanger W; Wright GW; Dave SS; Tan B; Zhao H; Rosenwald A; Muller-Hermelink HK; Gascoyne RD; Campo E; Jaffe ES; Smeland EB; Fisher RI; Kuehl WM; Chan WC; Staudt LM. "Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma." The Journal of experimental medicine. 2007; 204(3):633-43. Epub 2007 Mar 12. |
| Friedberg, J.W. and Fisher, R.I. In Leonard, J.P. and Coleman, M. (Eds). "Diffuse large B-cell NHL." Hodgkin's and non-Hodgkin's Lymphoma. Springer. (2006): 121-140. |
| Friedberg, J.W. and Fisher, R.I. In Canellos, G.P.; Lister, T.A. and Young, B. (Eds). "Large cell lymphoma: nodal, splenic". The lymphomas. Sanders, Philadelphia. (2006): 295-303. |
| Fisher, R.I. "Treatment of Diffuse Large B-Cell Lymphomas". Sem. In Hematology 43 (2006): 205-206. |
| Rimsza LM; Roberts RA; Campo E; Grogan TM; Bea S; Salaverria I; Zettl A; Rosenwald A; Ott G; Muller-Hermelink HK; Delabie J; Fisher RI; Unger JM; Leblanc M; Staudt LM; Jaffe ES; Gascoyne RD; Chan WC; Weisenburger DD; Greiner T; Braziel RM; Miller TP. "Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions." Blood. 2006; 107(3):1101-7. Epub 2005 Oct 20. |
| Khorana AA; Francis CW; Culakova E; Fisher RI; Kuderer NM; Lyman GH. "Thromboembolism in hospitalized neutropenic cancer patients." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(3):484-90. |
| Winter JN; Weller EA; Horning SJ; Krajewska M; Variakojis D; Habermann TM; Fisher RI; Kurtin PJ; Macon WR; Chhanabhai M; Felgar RE; Hsi ED; Medeiros LJ; Weick JK; Reed JC; Gascoyne RD. "Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study." Blood. 2006; 107(11):4207-13. Epub 2006 Jan 31. |
| Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ. "Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(19):3121-7. Epub 2006 Jun 05. |
| Dave SS; Fu K; Wright GW; Lam LT; Kluin P; Boerma EJ; Greiner TC; Weisenburger DD; Rosenwald A; Ott G; Müller-Hermelink HK; Gascoyne RD; Delabie J; Rimsza LM; Braziel RM; Grogan TM; Campo E; Jaffe ES; Dave BJ; Sanger W; Bast M; Vose JM; Armitage JO; Connors JM; Smeland EB; Kvaloy S; Holte H; Fisher RI; Miller TP; Montserrat E; Wilson WH; Bahl M; Zhao H; Yang L; Powell J; Simon R; Chan WC; Staudt LM; . "Molecular diagnosis of Burkitt's lymphoma." The New England journal of medicine. 2006; 354(23):2431-42. |
| Komrokji RS; Uppal NP; Khorana AA; Lyman GH; Kaplan KL; Fisher RI; Francis CW. "Venous thromboembolism in patients with diffuse large B-cell lymphoma." Leukemia & lymphoma. 2006; 47(6):1029-33. |
| Fisher SG; Fisher RI. "The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications." Current opinion in oncology. 2006; 18(5):417-24. |
| Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI; . "Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24(25):4143-9. Epub 2006 Aug 08. |
| Fisher, R.I.;. "Overview of southwest oncology group clinical trials in non-hodgkin lymphoma". Clin Adv Hematol Oncol 3 (2005): 544. |
| Fisher, R.I. "New horizons in the treatment of Hematological Malignancies". Am. J. Oncol. 4 (2005): 11-12. |
| Fisher RI. "Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(4):657-8. Epub 2004 Dec 21. |
| Rohatiner AZ; Gregory WM; Peterson B; Borden E; Solal-Celigny P; Hagenbeek A; Fisher RI; Unterhalt M; Arranz R; Chisesi T; Aviles A; Lister TA. "Meta-analysis to evaluate the role of interferon in follicular lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(10):2215-23. Epub 2005 Jan 31. |
| Song L; Zlobin A; Ghoshal P; Zhang Q; Houde C; Weijzen S; Jiang Q; Nacheva E; Yagan D; Davis E; Galiegue-Zouitina S; Catovsky D; Grogan T; Fisher RI; Miele L; Coignet LJ. "Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas." Cancer research. 2005; 65(11):4554-61. |
| Bea S; Zettl A; Wright G; Salaverria I; Jehn P; Moreno V; Burek C; Ott G; Puig X; Yang L; Lopez-Guillermo A; Chan WC; Greiner TC; Weisenburger DD; Armitage JO; Gascoyne RD; Connors JM; Grogan TM; Braziel R; Fisher RI; Smeland EB; Kvaloy S; Holte H; Delabie J; Simon R; Powell J; Wilson WH; Jaffe ES; Montserrat E; Muller-Hermelink HK; Staudt LM; Campo E; Rosenwald A; . "Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction." Blood. 2005; 106(9):3183-90. Epub 2005 Jul 26. |
| Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M. "Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(30):7565-73. Epub 2005 Sep 26. |
| Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP. "New treatment options have changed the survival of patients with follicular lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(33):8447-52. Epub 2005 Oct 17. |
| Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI. "Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma." Leukemia & lymphoma. 2005; 46(11):1569-73. |
| Friedberg JW; Fisher RI. "Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma." Expert review of anticancer therapy. 2004; 4(1):18-26. |
| Rimsza LM; Roberts RA; Miller TP; Unger JM; LeBlanc M; Braziel RM; Weisenberger DD; Chan WC; Muller-Hermelink HK; Jaffe ES; Gascoyne RD; Campo E; Fuchs DA; Spier CM; Fisher RI; Delabie J; Rosenwald A; Staudt LM; Grogan TM. "Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project." Blood. 2004; 103(11):4251-8. Epub 2004 Feb 19. |
| Solal-Céligny P; Roy P; Colombat P; White J; Armitage JO; Arranz-Saez R; Au WY; Bellei M; Brice P; Caballero D; Coiffier B; Conde-Garcia E; Doyen C; Federico M; Fisher RI; Garcia-Conde JF; Guglielmi C; Hagenbeek A; Haïoun C; LeBlanc M; Lister AT; Lopez-Guillermo A; McLaughlin P; Milpied N; Morel P; Mounier N; Proctor SJ; Rohatiner A; Smith P; Soubeyran P; Tilly H; Vitolo U; Zinzani PL; Zucca E; Montserrat E. "Follicular lymphoma international prognostic index." Blood. 2004; 104(5):1258-65. Epub 2004 May 04. |
| Fisher SG; Fisher RI. "The epidemiology of non-Hodgkin's lymphoma." Oncogene. 2004; 23(38):6524-34. |
| Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI. "Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(21):4302-11. Epub 2004 Sep 20. |
| Dave SS; Wright G; Tan B; Rosenwald A; Gascoyne RD; Chan WC; Fisher RI; Braziel RM; Rimsza LM; Grogan TM; Miller TP; LeBlanc M; Greiner TC; Weisenburger DD; Lynch JC; Vose J; Armitage JO; Smeland EB; Kvaloy S; Holte H; Delabie J; Connors JM; Lansdorp PM; Ouyang Q; Lister TA; Davies AJ; Norton AJ; Muller-Hermelink HK; Ott G; Campo E; Montserrat E; Wilson WH; Jaffe ES; Simon R; Yang L; Powell J; Zhao H; Goldschmidt N; Chiorazzi M; Staudt LM. "Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells." The New England journal of medicine. 2004; 351(21):2159-69. |
| Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA. "Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(4):607-14. |
| Rosenwald A; Wright G; Wiestner A; Chan WC; Connors JM; Campo E; Gascoyne RD; Grogan TM; Muller-Hermelink HK; Smeland EB; Chiorazzi M; Giltnane JM; Hurt EM; Zhao H; Averett L; Henrickson S; Yang L; Powell J; Wilson WH; Jaffe ES; Simon R; Klausner RD; Montserrat E; Bosch F; Greiner TC; Weisenburger DD; Sanger WG; Dave BJ; Lynch JC; Vose J; Armitage JO; Fisher RI; Miller TP; LeBlanc M; Ott G; Kvaloy S; Holte H; Delabie J; Staudt LM. "The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma." Cancer cell. 2003; 3(2):185-97. |
| Fisher RI. "Overview of non-Hodgkin's lymphoma: biology, staging, and treatment." Seminars in oncology. 2003; 30(2 Suppl 4):3-9. |
| Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; LeBlanc M; Gaynor ER; Rivkin SE; Fisher RI. "A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911." Blood. 2003; 102(5):1606-12. Epub 2003 May 08. |
| Velasquez WS; Lew D; Grogan TM; Spiridonidis CH; Balcerzak SP; Dakhil SR; Miller TP; Lanier KS; Chapman RA; Fisher RI; . "Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(10):1996-2003. |
| Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI; . "Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(13):2466-73. |
| Stiff PJ; Unger JM; Forman SJ; McCall AR; LeBlanc M; Nademanee AP; Bolwell BJ; Fisher RI; . "The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2003; 9(8):529-39. |
| Ganz PA; Moinpour CM; Pauler DK; Kornblith AB; Gaynor ER; Balcerzak SP; Gatti GS; Erba HP; McCoy S; Press OW; Fisher RI. "Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21(18):3512-9. |
| Rosenwald A; Wright G; Leroy K; Yu X; Gaulard P; Gascoyne RD; Chan WC; Zhao T; Haioun C; Greiner TC; Weisenburger DD; Lynch JC; Vose J; Armitage JO; Smeland EB; Kvaloy S; Holte H; Delabie J; Campo E; Montserrat E; Lopez-Guillermo A; Ott G; Muller-Hermelink HK; Connors JM; Braziel R; Grogan TM; Fisher RI; Miller TP; LeBlanc M; Chiorazzi M; Zhao H; Yang L; Powell J; Wilson WH; Jaffe ES; Simon R; Klausner RD; Staudt LM. "Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma." The Journal of experimental medicine. 2003; 198(6):851-62. |
| Fisher RI; Shah P. "Current trends in large cell lymphoma." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003; 17(10):1948-60. |
| Hahn T; Wolff SN; Czuczman M; Fisher RI; Lazarus HM; McCarthy PL; Vose J; Warren L; Watt R; . "The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2003; 9(10):667. |
| Godwin, J.W. and Fisher, R.I. "Diffuse large cell lymphomas. In: Grossland, M.L. (Ed.)". Malignant Lymphomas (2002): 112-126. |
| Rosenwald A; Wright G; Chan WC; Connors JM; Campo E; Fisher RI; Gascoyne RD; Muller-Hermelink HK; Smeland EB; Giltnane JM; Hurt EM; Zhao H; Averett L; Yang L; Wilson WH; Jaffe ES; Simon R; Klausner RD; Powell J; Duffey PL; Longo DL; Greiner TC; Weisenburger DD; Sanger WG; Dave BJ; Lynch JC; Vose J; Armitage JO; Montserrat E; López-Guillermo A; Grogan TM; Miller TP; LeBlanc M; Ott G; Kvaloy S; Delabie J; Holte H; Krajci P; Stokke T; Staudt LM; . "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma." The New England journal of medicine. 2002; 346(25):1937-47. |
| Fisher RI. "Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002; 20(22):4411-2. |
| Cheson, B.D. and Fisher, R.I. "Monoclonal antibodies in the treatment of hematologic malignancies- future directions." Monoclonal Antibody Therapy of Hematologic Malignancies (2001): 259-274. |
| Gaynor, E.G. and Fisher, R.I. In Haskell, C.M. (Eds). "Intermediate and high-grade lymphomas". Cancer Treatment. W.B. Saunders, Inc., Philadelphia. (2001): 1386-1390. |
| Fisher RI. "Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining." Journal of the National Cancer Institute. 2001; 93(1):4-5. |
| Gaynor ER; Unger JM; Miller TP; Grogan TM; White LA; Mills GM; Balcerzak SP; Varterasian M; LeBlanc M; Fisher RI. "Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001; 19(3):750-5. |
| Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI. "Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001; 19(2):389-97. |
| Braziel RM; Arber DA; Slovak ML; Gulley ML; Spier C; Kjeldsberg C; Unger J; Miller TP; Tubbs R; Leith C; Fisher RI; Grogan TM. "The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features." Blood. 2001; 97(12):3713-20. |
| Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W. "Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001; 19(13):3194-202. |
| Fisher RI. "Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting." Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7(7):1835-6. |
| Hahn T; Wolff SN; Czuczman M; Fisher RI; Lazarus HM; Vose J; Warren L; Watt R; McCarthy PL; . "The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2001; 7(6):308-31. |
| Press OW; LeBlanc M; Lichter AS; Grogan TM; Unger JM; Wasserman TH; Gaynor ER; Peterson BA; Miller TP; Fisher RI. "Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001; 19(22):4238-44. |
| Godwin JE; Fisher RI. "Diffuse large-cell lymphomas: a review of therapy." Clinical lymphoma. 2001; 2(3):155-63. |
| Fisher, R.I. "Diffuse large-cell lymphoma". Ann. Oncol. 11 (2000): 529-533. |
| Foon, K.A. and Fisher, R.I. In Beutler, E; Lichtman, M.A.; Coller, B.S.; Kipps, T.J. and Seligson, U. (Eds). "Lymphomas". Williams Hematology- McGraw Hill, New York (2000): 1237-1263. |
| Fisher, R.I.; Rosenberg, S.A. and Fyfe, G. "Long-term survival update for high dose proleukin in renal cancer". Cancer J. Sci. Am. 6 (2000): 855-857. |
| Fisher RI; Rosenberg SA; Fyfe G. "Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma." The cancer journal from Scientific American. 2000; 6 Suppl 1():S55-7. |
| Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T. "Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000; 18(10):2010-6. |
| Taylor CW; LeBlanc M; Fisher RI; Moore DF; Roach RW; Elias L; Miller TP. "Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial." Anti-cancer drugs. 2000; 11(9):695-700. |
| Fisher RI. "Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma." Seminars in oncology. 2000; 27(6 Suppl 12):2-8. |
| Cheson, B.D.; Horning, S.J.; Coiffier, B.; Shipp, M.A.; Fisher, R.I.; Connors, J.M.; Lister, T.A.; Vose, J.; Grillo-Lopez, A.; Hagenbeek, A.; Cabanillas, F.; Klippensten, D.; Hiddemann, W.; Castellino, R.; Harris, N.L.; Armitage, J.O.; Carter, W.; Hoppe, R.; Canellos, G.P.;. "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. NCI Sponsored International Working Group". J Clin Oncol 12 (1999): 1244-1253. |
| Atkins MB; Lotze MT; Dutcher JP; Fisher RI; Weiss G; Margolin K; Abrams J; Sznol M; Parkinson D; Hawkins M; Paradise C; Kunkel L; Rosenberg SA. "High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999; 17(7):2105-16. |
| Rizzo P; Carbone M; Fisher SG; Matker C; Swinnen LJ; Powers A; Di Resta I; Alkan S; Pass HI; Fisher RI. "Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma." Chest. 1999; 116(6 Suppl):470S-473S. |
| Moore DF; Brown TD; LeBlanc M; Dahlberg S; Miller TP; McClure S; Fisher RI. "Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial." Investigational new drugs. 1999; 17(2):169-72. |
| Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM. "MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998; 16(1):19-26. |
| Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI. "Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998; 16(1):48-55. |
| Winter JN; Andersen J; Reed JC; Krajewski S; Variakojis D; Bauer KD; Fisher RI; Gordon LI; Oken MM; Jiang S; Jeffries D; Domer P. "BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study." Blood. 1998; 91(4):1391-8. |
| Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI. "Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998; 16(2):574-8. |
| Gaynor ER; Fisher RI. "CHOP therapy: has shorter-course therapy had an impact on lymphomas?" Cancer investigation. 1998; 16(1):26-32. |
| Loeffler M; Brosteanu O; Hasenclever D; Sextro M; Assouline D; Bartolucci AA; Cassileth PA; Crowther D; Diehl V; Fisher RI; Hoppe RT; Jacobs P; Pater JL; Pavlovsky S; Thompson E; Wiernik P. "Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998; 16(3):818-29. |
| Fisher RI. "Relapse after successful treatment with immunotherapy: lessons for the future." The cancer journal from Scientific American. 1998; 4(2):78-9. |
| Miller TP; Dahlberg S; Cassady JR; Adelstein DJ; Spier CM; Grogan TM; LeBlanc M; Carlin S; Chase E; Fisher RI. "Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma." The New England journal of medicine. 1998; 339(1):21-6. |
| Fisher RI; Miller TP; Grogan TM. "New REAL clinical entities." The cancer journal from Scientific American. 1998; 4 Suppl 2():S5-12. |
| Hasenclever D; Diehl V. "A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease." The New England journal of medicine. 1998; 339(21):1506-14. |
| Fisher RI. "Treatment of grey zone lymphomas." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 1998; 9 Suppl 5():S121-3. |
| Gale RP; Park RE; Dubois R; Bierman PJ; Fisher RI; Loh KK; Peterson BA; Phillips GL; Portlock CS; Rosenblum D; Armitage JO. "Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma." Leukemia & lymphoma. 1998; 32(1-2):139-49. |
| Fisher, R.I. "CHOP vs. intensive chemotherapy in NHL". Cancer Chemother. & Pharmacol. 40 (1997): 42-46. |
| Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M. "Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study." The cancer journal from Scientific American. 1997; 3(3):157-62. |
| Fisher RI. "Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma." Cancer chemotherapy and pharmacology. 1997; 40 Suppl():S42-6. |
| Grogan TM; Miller TP; Fisher RI. "A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification." Hematology/oncology clinics of North America. 1997; 11(5):819-46. |
| Miller TP; LeBlanc M; Grogan TM; Fisher RI. "Follicular lymphomas: do histologic subtypes predict outcome?" Hematology/oncology clinics of North America. 1997; 11(5):893-900. |
| Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Fyfe G. "High-dose aldesleukin in renal cell carcinoma: long-term survival update." The cancer journal from Scientific American. 1997; 3 Suppl 1():S70-2. |
| Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J. "Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997." The cancer journal from Scientific American. 1997; 3 Suppl 1():S73-8. |
| Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH. "Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity." Clinical cancer research : an official journal of the American Association for Cancer Research. 1997; 3(1):39-46. |
| Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S. "Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma." Clinical cancer research : an official journal of the American Association for Cancer Research. 1997; 3(4):565-72. |
| Fisher, R.I. "Mantle-cell lymphoma: classification and therapeutic implications". Ann Oncol 7 (1996): 35-40. |
| Dana, B.W.; Dahlberg, S.; Nathwani, B.N.; Chase, E.; Coltman, C.; Miller, T.P. and Fisher, R.I. "Long-term follow-up of patients with low grade malignant lymphomas treated with Doxorubicin-based chemotherapy or chemoimmunotherapy." Classic Papers and Current Comments, J. Clin. Oncol. 1 (1996): 320-328. |
| Press, O.W.; Grogan, T.M. and Fisher, R.I. "Evaluation and management of mantle-cell lymphoma". Adv. Leuk. Lymphoma 6 (1996): 3-11. |
| Fyfe GA; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC. "Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996; 14(8):2410-1. |
| Fisher RI. "Report of workshop 5: early high-dose chemotherapy." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 1996; 7 Suppl 4():131-3. |
| Winter JN; Andersen J; Variakojis D; Gordon LI; Fisher RI; Oken MM; Neiman RS; Jiang S; Bauer KD. "Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas." Blood. 1996; 88(10):3919-25. |
| Hiddemann W; Longo DL; Coiffier B; Fisher RI; Cabanillas F; Cavalli F; Nadler LM; De Vita VT; Lister TA; Armitage JO. "Lymphoma classification--the gap between biology and clinical management is closing." Blood. 1996; 88(11):4085-9. |
| Weiss, G.R., Margolin, K.A., Sznol, M., Atkins, M.B., Oleksowicz, L., Isaacs, R., Sosman, J., Doroshow, J.H., Trehu, E.G., Dutcher, J.P., and Fisher, R.I. "A Phase II study of a 120-hour continuous intravenous infusion of Interleukin-6 for metastatic renal carcinoma." J. Immunother (1995): 52-56. |
| Swinnen LJ; Mullen GM; Carr TJ; Costanzo MR; Fisher RI. "Aggressive treatment for postcardiac transplant lymphoproliferation." Blood. 1995; 86(9):3333-40. |
| Sosman JA; Kefer C; Fisher RI; Jacobs CD; Pumfery P; Ellis TM. "A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients." Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 1995; 17(3):171-80. |
| Fisher RI; Oken MM. "Clinical practice guidelines: non-Hodgkin's lymphomas." Cleveland Clinic journal of medicine. 1995; 62 Suppl 1():SI6-42, quiz SI43-5. |
| Fisher RI; Dahlberg S; Nathwani BN; Banks PM; Miller TP; Grogan TM. "A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study." Blood. 1995; 85(4):1075-82. |
| Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC. "Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995; 13(3):688-96. |
| Alzona M; Jäck HM; Fisher RI; Ellis TM. "IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells." Journal of immunology (Baltimore, Md. : 1950). 1995; 154(1):9-16. |
| Gaynor ER; Fisher RI. "Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better?" Oncology (Williston Park, N.Y.). 1995; 9(12):1273-9; discussion 1283-4. |
| Sosman JA; Bartemes K; Offord KP; Kita H; Fisher SG; Kefer C; Ellis TA; Fisher RI; Higgins TJ; Gleich GJ. "Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration." Clinical cancer research : an official journal of the American Association for Cancer Research. 1995; 1(8):805-12. |
| Hawkins, M.J.; Atkins, M.B.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.R.; Margolin, K.A.; Rayner, A.A.; Sznol, M.; Parkinson, D.R.; Paietta, E.; et al.;. "A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma". J Immunother 15 (1994): 74-8. |
| Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP. "A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 1994; 5 Suppl 2():91-5. |
| Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM. "A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 1994; 5(5):447-52. |
| Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC. "Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994; 12(10):2153-9. |
| Fisher RI. "Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years." Cancer. 1994; 74(9 Suppl):2657-61. |
| Sparano JA; Fisher RI; Weiss GR; Margolin K; Aronson FR; Hawkins MJ; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH. "Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors." Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 1994; 16(3):216-23. |
| Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G. "Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994; 12(12):2667-76. |
| Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI. "Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994; 12(8):1553-60. |
| Saez R; Dahlberg S; Appelbaum FR; Hartsock RJ; Lemaistre F; Coltman CA; Fisher RI. "Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study." Hematological oncology. 1994; 12(2):75-85. |
| Alzona M; Jäck HM; Fisher RI; Ellis TM. "CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity." Journal of immunology (Baltimore, Md. : 1950). 1994; 153(7):2861-7. |
| Margolin K; Aronson FR; Sznol M; Atkins MB; Gucalp R; Fisher RI; Sunderland M; Doroshow JH; Ernest ML; Mier JW. "Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma." Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 1994; 15(2):147-53. |
| Fabian CJ; Mansfield CM; Dahlberg S; Jones SE; Miller TP; Van Slyck E; Grozea PN; Morrison FS; Coltman CA; Fisher RI. "Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study." Annals of internal medicine. 1994; 120(11):903-12. |
| Nand S; Sosman J; Godwin JE; Fisher RI. "A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes." Blood. 1994; 83(2):357-60. |
| Fisher, R.I. "Advances in clinical research and treatment." Semin. Oncol (1993): 1-2. |
| Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP. "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma." The New England journal of medicine. 1993; 328(14):1002-6. |
| Swinnen LJ; Fisher RI. "OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation." Current opinion in nephrology and hypertension. 1993; 2(4):670-8. |
| Ellis TM; Simms PE; Slivnick DJ; Jäck HM; Fisher RI. "CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells." Journal of immunology (Baltimore, Md. : 1950). 1993; 151(5):2380-9. |
| . "A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project." The New England journal of medicine. 1993; 329(14):987-94. |
| Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J. "Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993; 11(8):1496-505. |
| Poplin E; Fleming T; MacDonald JS; Eisenberg P; Fisher RI; Conrad ME. "Amonafide treatment of refractory esophageal cancer. A Southwest Oncology Group study." Investigational new drugs. 1993; 11(1):47-51. |
| Sparano JA; Fisher RI; Sunderland M; Margolin K; Ernest ML; Sznol M; Atkins MB; Dutcher JP; Micetich KC; Weiss GR. "Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993; 11(10):1969-77. |
| Dana BW; Dahlberg S; Nathwani BN; Chase E; Coltman C; Miller TP; Fisher RI. "Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993; 11(4):644-51. |
| Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R. "Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993; 11(4):661-70. |
| Weiss, G.R., Margolin, K.A., Aronson, F.R., Sznol, M., Atkins, M.B., Dutcher, J.P., Gaynor, E.R., Boldt, D.H., Doroshow, J.R., Bar, M.H., Hawkins, M.J., Demchak, P.A., Gulcap, R., and Fisher, R.I.:. "A randomized Phase II trial of continuous infusion Interleukin-2 or bolus injection Interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma." J. Clin. Oncol. (1992): 270-275. |
| Meerwaldt, J.H., Coleman, C.N., Fisher, R.I., Lister, T.A., and Diehl, V. "Role of additional radiotherapy in advanced stage of Hodgkin's disease." Ann. Oncol. (1992): 83-85. |
| Bayer RA; Gaynor ER; Fisher RI. "Bleomycin in non-Hodgkin's lymphoma." Seminars in oncology. 1992; 19(2 Suppl 5):46-52; discussion 52-3. |
| McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM. "Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2." Cancer research. 1992; 52(22):6318-22. |
| Maecker HT; Jokinen DM; Fisher RI. "T cell receptor expression can switch on and off at a posttranslational level." Journal of immunology (Baltimore, Md. : 1950). 1992; 149(5):1619-25. |
| Micetich KC; Futscher B; Koch D; Fisher RI; Erickson LC. "Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer." Journal of the National Cancer Institute. 1992; 84(4):256-60. |
| Nand S; Ellis T; Messmore H; Fisher SG; Gaynor E; Fisher RI. "Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1992; 6(3):220-3. |
| Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher SG; Fisher RI. "Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience." Seminars in oncology. 1992; 19(3 Suppl 9):102-9. |
| Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI. "Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(1):25-38. |
| Weick JK; Dahlberg S; Fisher RI; Dana B; Miller TP; Balcerzak SP; Pierce HI. "Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(5):748-53. |
| Dahlberg S; Miller TP; Fisher RI. "A clinical phase II study of ProMACE-CytaBOM." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(5):888. |
| Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC. "Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 1991; 2 Suppl 1():33-5. |
| Dabich L; Dahlberg S; Hartsock RJ; LoBuglio AF; Liepman MK; Grozea PN; Eyre HJ; Weick JK; Bonnet JD; Coltman CA. "Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group." Cancer investigation. 1991; 9(6):613-20. |
| Gaynor ER; Fisher RI. "Chemotherapy and combined modality treatment in Hodgkin's disease." Current opinion in oncology. 1991; 3(5):822-9. |
| Landis RC; Friedman ML; Fisher RI; Ellis TM. "Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals." Journal of immunology (Baltimore, Md. : 1950). 1991; 146(1):128-35. |
| Margolin KA; Aronson FR; Sznol M; Atkins MB; Ciobanu N; Fisher RI; Weiss GR; Doroshow JH; Bar MH; Hawkins MJ. "Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma." Journal of immunotherapy : official journal of the Society for Biological Therapy. 1991; 10(3):214-20. |
| Gaynor ER; Fisher RI. "Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma." Seminars in oncology. 1991; 18(5 Suppl 7):12-7. |
| Miller TP; Dahlberg S; Salmon SE; Williamson SK; Belt RJ; Dana BW; Fisher RI. "Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(7):1204-9. |
| Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH; Sznol M; Mier J; Sparano J; Fisher RI; Weiss G. "A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(4):641-8. |
| Stiff PJ; McKenzie RS; Potempa LD; Albain K; Koch D; Braud E; Bansal VK; Weidner MK; Lanzotti VJ; Chun HG. "A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991; 9(8):1487-94. |
| Sznol, M., Mier, J.W., Sporano, J., Gaynor, E., Weiss, G., Margolin, K., Bar, M.H., Hawkins, M.J., Atkins, M., Dutcher, J.P., Fisher, R.I., Boldt, D.H., Doroshow, J.H., Louie, A., and Aronson, F.R. "A Phase I study of high dose Interleukin-2 in combination with interferon-alfa 2B". J. Biol. Resp. Mod. (1990): 529-538. |
| Fisher RI; Stiff PJ. "Treatment options for recurrent lymphomas." Seminars in oncology. 1990; 17(2 Suppl 4):63-7. |
| Dana BW; Dahlberg S; Miller TP; Hartsock RJ; Balcerzak S; Coltman CA; Carden JO; Hartley K; Fisher RI. "m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990; 8(7):1155-62. |
| Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI. "Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990; 8(12):1951-8. |
| Swinnen LJ; Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson MR; Heroux AL; Dizikes GJ; Pifarre R; Fisher RI. "Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients." The New England journal of medicine. 1990; 323(25):1723-8. |
| Fisher RI. "CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma." Important advances in oncology. 1990; |
| Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH. "Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990; 8(10):1630-6. |
| Albain KS; Swinnen LJ; Erickson LC; Stiff PJ; Fisher RI. "Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model." Cancer chemotherapy and pharmacology. 1990; 27(1):33-40. |
| Slivnick DJ; Ellis TM; Nawrocki JF; Fisher RI. "The impact of Hodgkin's disease on the immune system." Seminars in oncology. 1990; 17(6):673-82. |
| Weisfuse IB; Graham DJ; Will M; Parkinson D; Snydman DR; Atkins M; Karron RA; Feinstone S; Rayner AA; Fisher RI. "An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells." The Journal of infectious diseases. 1990; 161(4):647-52. |
| Nand S; Messmore H; Fisher SG; Bird ML; Schulz W; Fisher RI. "Leukemic transformation in polycythemia vera: analysis of risk factors." American journal of hematology. 1990; 34(1):32-6. |
| Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ. "Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990; 8(7):1138-47. |
| Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH. "Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma." Journal of the National Cancer Institute. 1990; 82(17):1397-402. |
| Sobotka PA; McMannis J; Fisher RI; Stein DG; Thomas JX. "Effects of interleukin 2 on cardiac function in the isolated rat heart." The Journal of clinical investigation. 1990; 86(3):845-50. |
| Ellis TM; Fisher RI. "Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells." Journal of immunology (Baltimore, Md. : 1950). 1989; 142(8):2949-54. |
| Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI. "Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma." Journal of immunology (Baltimore, Md. : 1950). 1989; 143(12):4282-6. |
| Fisher RI. "Picking winners and losers in diffuse small-cell lymphomas." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989; 7(8):991-2. |
| Futscher BW; Micetich KC; Barnes DM; Fisher RI; Erickson LC. "Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells." Cancer communications. 1989; 1(1):65-73. |
| Dutcher JP; Creekmore S; Weiss GR; Margolin K; Markowitz AB; Roper M; Parkinson D; Ciobanu N; Fisher RI; Boldt DH. "A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989; 7(4):477-85. |
| Margolin KA; Rayner AA; Hawkins MJ; Atkins MB; Dutcher JP; Fisher RI; Weiss GR; Doroshow JH; Jaffe HS; Roper M. "Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989; 7(4):486-98. |
| Slivnick DJ; Nawrocki JF; Fisher RI. "Immunology and cellular biology of Hodgkin's disease." Hematology/oncology clinics of North America. 1989; 3(2):205-20. |
| Gaynor ER; Fisher RI. "Recent advances in the management of non-Hodgkin's lymphomas." Disease-a-month : DM. 1989; 35(9):597-650. |
| Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI. "A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989; 7(2):276-84. |
| Longo DL; Glatstein E; Duffey PL; Ihde DC; Hubbard SM; Fisher RI; Jaffe ES; Gilliom M; Young RC; DeVita VT. "Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989; 7(9):1295-302. |
| Swinnen LJ; Barnes DM; Fisher SG; Albain KS; Fisher RI; Erickson LC. "1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking." Cancer research. 1989; 49(6):1383-9. |
| Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI. "Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas." Seminars in hematology. 1988; 25(2 Suppl 2):17-22. |
| Ellis TM; Creekmore SP; McMannis JD; Braun DP; Harris JA; Fisher RI. "Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2." Cancer research. 1988; 48(22):6597-602. |
| Ellis TM; McMannis JD; Chua AO; Gubler U; Fisher RI. "Interleukin-1-independent activation of human T lymphocytes stimulated by anti-CD3 and a Hodgkin's disease cell line with accessory cell activity." Cellular immunology. 1988; 116(2):352-66. |
| McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM. "In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2." Journal of immunology (Baltimore, Md. : 1950). 1988; 140(4):1335-40. |
| Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA. "Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial." Annals of internal medicine. 1988; 108(4):518-23. |
| Kozeny GA; Nicolas JD; Creekmore S; Sticklin L; Hano JE; Fisher RI. "Effects of interleukin-2 immunotherapy on renal function." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988; 6(7):1170-6. |
| Gaynor ER; Vitek L; Sticklin L; Creekmore SP; Ferraro ME; Thomas JX; Fisher SG; Fisher RI. "The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells." Annals of internal medicine. 1988; 109(12):953-8. |
| Nawrocki JF; Kirsten ES; Fisher RI. "Biochemical and structural properties of a Hodgkin's disease-related membrane protein." Journal of immunology (Baltimore, Md. : 1950). 1988; 141(2):672-80. |
| Fisher RI; Miller TP; Dana BW; Jones SE; Dahlberg S; Coltman CA. "Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas." Seminars in hematology. 1987; 24(2 Suppl 1):21-5. |
| Stiff PJ; Koester AR; Weidner MK; Dvorak K; Fisher RI. "Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing." Blood. 1987; 70(4):974-8. |
| Nand S; Fisher SG; Salgia R; Fisher RI. "Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987; 5(12):1998-2003. |
| Nand S; Messmore HL; Patel R; Fisher SG; Fisher RI. "Neurotoxicity associated with systemic high-dose cytosine arabinoside." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1986; 4(4):571-5. |
| Nagai H; Fisher RI; Cossman J; Oppenheim JJ. "Decreased expression of class II major histocompatibility antigens on monocytes from patients with Hodgkin's disease." Journal of leukocyte biology. 1986; 39(3):313-21. |
| Fisher, R.I. "Natural history of non-Hodgkin's lymphomas: Implications for marrow transplantation research." Autologous Bone Marrow Transplantation: Proceedings of the First International Symposium. (1985): 63-66. |
| Fisher RI; Young RC; Longo D; DeVita VT. "ProMACE-MOPP combination chemotherapy for diffuse lymphomas." Seminars in oncology. 1985; 12(1 Suppl 2):29-32. |
| Hecht TT; Longo DL; Cossman J; Bolen JB; Hsu SM; Israel M; Fisher RI. "Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells." Journal of immunology (Baltimore, Md. : 1950). 1985; 134(6):4231-6. |
| Boccia RV; Longo DL; Lieber ML; Jaffe ES; Fisher RI. "Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma." Cancer. 1985; 56(9):2295-7. |
| Fisher RI; Cossman J; Diehl V; Volkman DJ. "Antigen presentation by Hodgkin's disease cells." Journal of immunology (Baltimore, Md. : 1950). 1985; 135(5):3568-71. |
| Geffen DB; Fisher RI; Longo DL; Young RC; DeVita VT. "Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1985; 3(5):646-53. |
| Silver BA; Bostick-Bruton FW; Neckers L; Fisher RI. "Deficient helper cell function as a cause of diminished pokeweed mitogen blastogenic responses in patients with non-Hodgkin's lymphomas." Cancer. 1984; 54(12):2936-42. |
| Longo DL; Young RC; Hubbard SM; Wesley M; Fisher RI; Jaffe E; Berard C; DeVita VT. "Prolonged initial remission in patients with nodular mixed lymphoma." Annals of internal medicine. 1984; 100(5):651-6. |
| Cossman J; Jaffe ES; Fisher RI. "Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features." Cancer. 1984; 54(7):1310-7. |
| Shackney SE; Levine AM; Fisher RI; Nichols P; Jaffe E; Schuette WH; Simon R; Smith CA; Occhipinti SJ; Parker JW. "The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases." The Journal of clinical investigation. 1984; 73(4):1201-14. |
| Fisher RI; Bates SE; Bostick-Bruton F; Tuteja N; Diehl V. "Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses." Journal of immunology (Baltimore, Md. : 1950). 1984; 132(5):2672-7. |
| Cossman J; Chused TM; Fisher RI; Magrath I; Bollum F; Jaffe ES. "Diversity of immunological phenotypes of lymphoblastic lymphoma." Cancer research. 1983; 43(9):4486-90. |
| Fisher RI; Bostick-Bruton F; Sauder DN; Scala G; Diehl V. "Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures." Journal of immunology (Baltimore, Md. : 1950). 1983; 130(6):2666-70. |
| Blayney DW; Blattner WA; Robert-Guroff M; Jaffe ES; Fisher RI; Bunn PA; Patton MG; Rarick HR; Gallo RC. "The human T-cell leukemia-lymphoma virus in the southeastern United States." JAMA : the journal of the American Medical Association. 1983; 250(8):1048-52. |
| Blayney DW; Jaffe ES; Fisher RI; Schechter GP; Cossman J; Robert-Guroff M; Kalyanaraman VS; Blattner WA; Gallo RC. "The human T-cell leukemia/lymphoma virus, lymphoma, lytic bone lesions, and hypercalcemia." Annals of internal medicine. 1983; 98(2):144-51. |
| Fisher RI; DeVita VT; Hubbard SM; Longo DL; Wesley R; Chabner BA; Young RC. "Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy." Annals of internal medicine. 1983; 98(3):304-9. |
| Gallo RC; Kalyanaraman VS; Sarngadharan MG; Sliski A; Vonderheid EC; Maeda M; Nakao Y; Yamada K; Ito Y; Gutensohn N; Murphy S; Bunn PA; Catovsky D; Greaves MF; Blayney DW; Blattner W; Jarrett WF; zur Hausen H; Seligmann M; Brouet JC; Haynes BF; Jegasothy BV; Jaffe E; Cossman J; Broder S; Fisher RI; Golde DW; Robert-Guroff M. "Association of the human type C retrovirus with a subset of adult T-cell cancers." Cancer research. 1983; 43(8):3892-9. |
| Fisher RI. "Non-Hodgkin's lymphomas after treatment of Hodgkin's disease." Archives of internal medicine. 1983; 143(3):427. |
| Vermess, M.; Doppman, J.L.; Sugarbaker, P.H.; Fisher, R.I.; O'Leary, T.J.; Chatterji, D.C.; Grimes, G.; Adamson, R.H.; Willis, M.; Edwards, B.K.;. "Computed tomography of the liver and spleen with intravenous lipoid contrast material: review of 60 examinations". AJR Am J Roentgenol 138 (1982): c Neoplasms/radiography. |
| Thomas, J.L.; Bernardino, M.E.; Vermess, M.; Barnes, P.A.; Fuller, L.M.; Hagemeister, F.B.; Doppman, J.; Fisher, R.I.; Longo, D.L.;. "EOE-13 in the detection of hepatosplenic lymphoma". Radiology 145 (1982): c Neoplasms/*radiography. |
| Fisher RI. "Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease." Cancer treatment reports. 1982; 66(4):681-7. |
| Silver BA; Barlock AL; Lippman ME; Anderson T; Fisher RI. "Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors." Cancer treatment reports. 1982; 66(5):1229-30. |
| Vanhaelen CP; Fisher RI. "Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease." The American journal of medicine. 1982; 72(3):385-90. |
| Levine AS; Brennan MF; Ramu A; Fisher RI; Pizzo PA; Glaubiger DL. "Controlled clinical trials of nutritional intervention as an adjunct to chemotherapy, with a comment on nutrition and drug resistance." Cancer research. 1982; 42(2 Suppl):774s-781s. |
| Fisher RI; Bostick-Bruton F. "Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide." Journal of immunology (Baltimore, Md. : 1950). 1982; 129(4):1770-4. |
| Fisher RI; Silver BA; Vanhaelen CP; Jaffe ES; Cossman J. "Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin." Cancer research. 1982; 42(6):2465-9. |
| Vermess M; Bernardino ME; Doppman JL; Fisher RI; Thomas JL; Velasquez WS; Fuller LM; Russo A. "Use of intravenous liposoluble contrast material for the examination of the liver and spleen in lymphoma." Journal of computer assisted tomography. 1981; 5(5):709-13. |
| Fisher RI; Vanhaelen C; Bostick F. "Increased sensitivity to normal adherent suppressor cells in untreated advanced Hodgkin's disease." Blood. 1981; 57(5):830-5. |
| Ozols RF; Fisher RI; Anderson T; Makuch R; Young RC. "Peritoneoscopy in the management of ovarian cancer." American journal of obstetrics and gynecology. 1981; 140(6):611-9. |
| Vanhaelen CP; Fisher RI. "Increased sensitivity of lymphocytes from patients with Hodgkin's disease to concanavalin A-induced suppressor cells." Journal of immunology (Baltimore, Md. : 1950). 1981; 127(3):1216-20. |
| Popp MB; Fisher RI; Wesley R; Aamodt R; Brennan MF. "A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival." Surgery. 1981; 90(2):195-203. |
| Popp MB; Fisher RI; Simon RM; Brennan MF. "A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance." Cancer treatment reports. 1981; 65 Suppl 5():129-35. |
| Vanhaelen CP; Fisher RI; Appella E; Ramanathan L. "Lack of histocompatibility antigens on a murine ovarian teratocarcinoma." Cancer research. 1981; 41(8):3186-91. |
| Fisher RI; Terry WD; Hodes RJ; Rosenberg SA; Makuch R; Gordon HG; Fisher SG. "Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial." The Surgical clinics of North America. 1981; 61(6):1267-77. |
| Micetich KC; Jensen-Akula M; Mandard JC; Fisher RI. "Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy." The American journal of medicine. 1981; 71(6):967-72. |
| Vanhaelen CP; Fisher RI. "Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer." Cancer research. 1981; 41(3):980-3. |
| Fisher RI; Jones RB; DeVita VT; Simon RM; Garvin AJ; Berard CW; Young RC. "Natural history of malignant lymphomas with divergent histologies at staging evaluation." Cancer. 1981; 47(8):2022-5. |
| Fisher RI; Hubbard SM; DeVita VT; Berard CW; Wesley R; Cossman J; Young RC. "Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma." Blood. 1981; 58(1):45-51. |
| Vermess M; Doppman JL; Sugarbaker P; Fisher RI; Chatterji DC; Luetzeler J; Grimes G; Girton M; Adamson RH. "Clinical trials with a new intravenous liposoluble contrast material for computed tomography of the liver and spleen." Radiology. 1980; 137(1 Pt 1):217-22. |
| Morens DM; Bregman DJ; West CM; Greene MH; Mazur MH; Dolin R; Fisher RI. "An outbreak of varicella-zoster virus infection among cancer patients." Annals of internal medicine. 1980; 93(3):414-9. |
| Fisher RI; Mandell GL; Bostick F; McMenamin MG; Anderson T. "Chlorozotocin, an anti-tumour agent lacking bone marrow toxicity at therapeutic doses: effects on lymphocyte subpopulations in mice." Clinical and experimental immunology. 1980; 39(2):416-25. |
| Dunnick NR; Fisher RI; Chu EW; Young RC. "Percutaneous aspiration of retroperitoneal lymph nodes in ovarian cancer." AJR. American journal of roentgenology. 1980; 135(1):109-13. |
| Fisher RI; DeVita VT; Bostick F; Vanhaelen C; Howser DM; Hubbard SM; Young RC. "Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease." Annals of internal medicine. 1980; 92(5):595-9. |
| Chabner BA; Fisher RI; Young RC; DeVita VT. "Staging of non-Hodgkin's lymphoma." Seminars in oncology. 1980; 7(3):285-91. |
| Young, R.C.; Howser, D.M.; Anderson, T.; Fisher, R.I.; Jaffe, E.; DeVita, V.T., Jr.;. "Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy". Am J Med 66 (1979): radiation effects. |
| Mandell GL; Fisher RI; Bostick F; Young RC. "Ovarian cancer: a solid tumor with evidence of normal cellular immune function but abnormal B cell function." The American journal of medicine. 1979; 66(4):621-4. |
| Fisher RI; Chabner BA; Myers CE. "Phase II study of high-dose methotrexate in patients with advanced malignant melanoma." Cancer treatment reports. 1979; 63(1):147-8. |
| Fisher RI; DeVita VT; Hubbard SP; Simon R; Young RC. "Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse." Annals of internal medicine. 1979; 90(5):761-3. |
| Ozols RF; Locker GY; Doroshow JH; Grotzinger KR; Myers CE; Fisher RI; Young RC. "Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin." Cancer treatment reports. 1979; 63(2):269-73. |
| Ozols RF; Grotzinger KR; Fisher RI; Myers CE; Young RC. "Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer." Cancer research. 1979; 39(8):3202-8. |
| Young RC; Chabner BA; Hubbard SP; Fisher RI; Bender RA; Anderson T; Simon RM; Canellos GP; DeVita VT. "Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy." The New England journal of medicine. 1978; 299(23):1261-6. |
| Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC. "Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma." Cancer. 1978; 42(5):2157-61. |
| Fisher RI; Kubota TT; Mandell GL; Broder S; Young RC. "Regression of a T-cell lymphoma after administration of antithymocyte globulin." Annals of internal medicine. 1978; 88(6):799-800. |
| Hande KR; Fisher RI; DeVita VT; Chabner BA; Young RC. "Diffuse histiocytic lymphoma involving the gastrointestinal tract." Cancer. 1978; 41(5):1984-9. |
| Fisher RI; Young RC. "Chemotherapy of ovarian cancer." The Surgical clinics of North America. 1978; 58(1):143-50. |
| Young NA; Kwon-Chung KJ; Kubota TT; Jennings AE; Fisher RI. "Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma." Journal of clinical microbiology. 1978; 7(6):589-94. |
| Young RC; Fisher RI. "The staging and treatment of epithelial ovarian cancer." Canadian Medical Association journal. 1978; 119(3):249-56. |
| Bender RA; Anderson T; Fisher RI; Young RC. "Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma." American journal of hematology. 1978; 5(3):203-9. |
| Fisher RI; DeVita VT; Johnson BL; Simon R; Young RC. "Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy." The American journal of medicine. 1977; 63(2):177-82. |
| Anderson T; Bender RA; Fisher RI; DeVita VT; Chabner BA; Berard CW; Norton L; Young RC. "Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup." Cancer treatment reports. 1977; 61(6):1057-66. |
| Fisher RI; Young RC. "Advances in the staging and treatment of ovarian cancer." Cancer. 1977; 39(2 Suppl):967-72. |
| DeVita VT; Fisher RI. "Malignant melanoma: prognostic factors and therapeutic results." The West Virginia medical journal. 1977; 73(8):167-72. |
| Hande KR; Reimer RR; Fisher RI. "Comparison of nodal primary versus extranodal primary histiocytic lymphoma." Cancer treatment reports. 1977; 61(6):999-1000. |
| DeVita, V.T., Jr.; Fisher, R.I.;. "Natural history of malignant melanoma as related to therapy". Cancer Treat Rep 60 (1976): c Neoplasms/pathology. |
| Fisher RI; Neifeld JP; Lippman ME. "Oestrogen receptors in human malignant melanoma." Lancet. 1976; 2(7981):337-9. |
| Neifeld JP; Lippman ME; Fisher RI. "Receptors for steroid hormones in human melanoma." Surgical forum. 1976; 27(62):108-10. |
| Fisher RI; Jaffe ES; Braylan RC; Andersen JC; Tan HK. "Immunoblastic lymphadenopathy. Evolution into a malignant lymphoma with plasmacytoid features." The American journal of medicine. 1976; 61(4):553-9. |
| Henkart PA; Fisher RI. "Characterization of the lymphocyte surface receptors for Con A and PHA." Journal of immunology (Baltimore, Md. : 1950). 1975; 114(2 Pt 1):710-4. |
| Fisher RI. "Cognitive appraisal: an examination." The Journal of psychology. 1974; 88(1st Half):147-52. |
| Dickler HB; Adkinson NF; Fisher RI; Terry WD. "Lymphocytes in patients with variable immunodeficiency and panhypogammaglobulinemia. Evaluation of B and T cell surface markers and a proposed classification." The Journal of clinical investigation. 1974; 53(3):834-40. |
| Miller, T.P., Grogan, T.M., Dahlberg, S., Spier, C.M., Braziel, R.M., Banks, P.M., Foucar, K., Kjeldsberg, C.R., Levy, N., Nathwani, B.N., Schnitzer, B., Tubbs, R.R., Gaynor, E.R. and Fisher, R.I. "Prognostic significance of the Ki-67 associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group Trial". Blood: 1460-1466. |
| Fisher, R.I.; Bernstein, S.; Kahl, B.S.; Djulbegovic, B; Robertson, M.J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J.P.; Lional, S.; Stadtmauer, E.A.; O'Connor, O.A.; Shi, H.; Boral, A.L. and Goy, A. "Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma." Journal of Clinical Oncology. |
| Anolik, J.H.; Friedberg, J.W.; Zheng, B.; Barnard, J.; Owen, T.; Cushing, E.; Kelly, J.; Milner, E.C.B.; Fisher, R.I. and Sanz, I. "B-cell reconstitution after rituximab treatment of lymphoma recapitulates B-cell ontogeny (In Press)". Clinical Immunology. |
| Wiestner, A.; Tehrani, M.; Chiorazzi, M.; Wright, G.; Gibellini, F.; Nakayama, K.; Liu, H.; Rosenwald, A.; Muller-Hermelink, H.K.; Ott, G.; Chan, W.C.; Greiner, T.C.; Weisenburger, D.D.; Vose, J.; Armitage, J.O.; Gascoyne, R.D.; Connors, J.M.; Campo, E.; Montserrat, E.; Bosch, F.; Smeland, E.B.; Kvaloy, S.; Holte, H.; Delabie, J.; Fisher, R.I.; Grogan, T.M.; Miller, T.P.; Wilson, W.H.; Jaffe, E.S. and Staudt, L.M. for the Lymphoma/Leukemia Molecular Profiling Project. "Point Mutations and Genomic Deletions in Cyclin DI Create Stable Truncated mRNAs that are Associated with Increased Proliferation Rate and Shorter Survival in Mantle Cell Lymphoma." Blood.. |
| Bernstein, S.H.; Unger, J.M.; LeBlanc, M.; Friedberg, J.; Miller, T.P. and Fisher, R.I. "The Role of Central Nervous System (CNS) Prophylaxis For Patients with Aggressive non-Hodgkin's Lymphoma: A 20 Year Follow-Up Analysis of Southwest Oncology Group (SWOG) 8516." Journal of Clinical Oncology. |
| Brown, J.R.; Friedberg, J.W.; Feng, Y.; Scofield, S.; Phillips, K.; Dal Sin, P.; Joyce, R.; Takvorian, R.W.; Fisher, D.C.; Fisher, R.I.; Liesveld, J.; Marquis, D.; Neuberg, D and Freedman, A.S. "A Phase 2 Study of Concurrent Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas." British Journal of Hematology. |
| Biswas, T.; Dhakal, S.; Chen, R.; Hyrien, O.; Bernstein, S.H.; Friedberg, J.W.; Fisher, R.I.; Liesveld, J.; Phillips, G.; Constine, L.S. "Involved Field Radiation after Autologous Stem Cell Transplant for Large B-cell Lymphoma in the Rituximab Era". Int. J. Radiat. Oncol. Biol. Phys.. |
| Sweetenham, JW; Goldman, B; LeBlanc, ML; Cook, JR; Tubbs, RR; Press, OW; Maloney, DG; Fisher, R.I.; Rimsza, LM; Braziel, RM; His, ED. "Prognostic Value of Regulatory T-Cellsl, Lymphoma Associated Macrophages and MUM-1 Expression in Follicular Lymphoma Treated Before and After the Introduction of Monoclonal Antibody Therapy". Annals of Oncology. |
